Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: Systematic review

Vaccine

Volumn 28, Issue 38, 2010, Pages 6128-6136

  O'Loughlin, Rosalyn E ^a   Edmond, Karen ^a   Mangtani, Punam ^a   Cohen, Adam L ^b   Shetty, Sharmila ^b   Hajjeh, Rana ^b   Mulholland, Kim ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Case control studies; Haemophilus influenza type b vaccine; Vaccine effectiveness

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; PNEUMOCOCCUS VACCINE;

CASE CONTROL STUDY; DATA ANALYSIS; DRUG EFFICACY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS MENINGITIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

BACTERIAL CAPSULES; CASE-CONTROL STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS VACCINES; HUMANS; VACCINES, CONJUGATE;

EID: 77955659349     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.107     Document Type: Review

References (45)

1. World Health Organization Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era: a global review of incidence, age distributions, and case-fatality rates 2002, Department of Vaccines and Biologicals, World Health Organization, WHO/V&B/02.18.
2. Progress introducing Haemophilus influenzae type b vaccine in low-income countries, 2004-2008. Wkly Epidemiol Rec 2008; 83:61-8.
3. World Health Organization The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 47:445-452.
4. World Health Organization. Global framework for immunization monitoring and surveillance. Department of Immunizations Vaccines and Biologicals, World Health Organization, WHO/IVB/07.06; 2007.
5. Farrington C.P. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993, 22:742-746.
6. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007, 4:e296.
7. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
8. Loughlin A.M., Marchant C.D., Lett S., Shapiro E.D. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age. Pediatr Infect Dis J 1992, 11:374-379.
9. Vadheim C.M., Greenberg D.P., Eriksen E., Hemenway L., Christenson P., Ward B., et al. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study. Pediatr Infect Dis J 1994, 13:274-280.
10. Harrison L.H., Tajkowski C., Croll J., Reid R., Hu D., Brenneman G., et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994, 125:571-576.
11. Jafari H.S., Adams W.G., Robinson K.A., Plikaytis B.D., Wenger J.D. Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. The Haemophilus Influenzae Study Group. Am J Public Health 1999, 89:364-368.
12. Adegbola R.A., Secka O., Lahai G., Lloyd-Evans N., Njie A., Usen S., et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366:144-150.
13. Bower C., Condon R., Payne J., Burton P., Watson C., Wild B. Measuring the impact of conjugate vaccines on invasive Haemophilus influenzae type b infection in Western Australia. Aust N Z J Public Health 1998, 22:67-72.
14. Baqui A.H., El Arifeen S., Saha S.K., Persson L., Zaman K., Gessner B.D., et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine on prevention of pneumonia and meningitis in Bangladeshi children: a case-control study. Pediatr Infect Dis J 2007, 26:565-571.
15. Daza P., Banda R., Misoya K., Katsulukuta A., Gessner B.D., Katsande R., et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006, 24:6232-6239.
16. Lee E.H., Lewis R.F., Makumbi I., Kekitiinwa A., Ediamu T.D., Bazibu M., et al. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health 2008, 13:495-502.
17. Lee E.H., Corcino M., Moore A., Garib Z., Pena C., Sanchez J., et al. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic. Rev Panam Salud Publica 2008, 24:161-168.
18. Lewis R.F., Kisakye A., Gessner B.D., Duku C., Odipio J.B., Iriso R., et al. Action for child survival: elimination of Haemophilus influenzae type b meningitis in Uganda. Bull World Health Organ 2008, 86:292-301.
19. Muganga N., Uwimana J., Fidele N., Gahimbare L., Gessner B.D., Mueller J.E., et al. Haemophilus influenzae type b conjugate vaccine impact against purulent meningitis in Rwanda. Vaccine 2007, 25:7001-7005.
20. de Andrade A.L., de Andrade J.G., Martelli C.M., e Silva S.A., de Oliveira R.M., Costa M.S., et al. Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 2004, 33:173-181.
21. de la Hoz F., Higuera A.B., Di Fabio J.L., Luna M., Naranjo A.G., de la Luz Valencia M., et al. Effectiveness of Haemophilus influenzae type b vaccination against bacterial pneumonia in Colombia. Vaccine 2004, 23:36-42.
22. Herceg A. The decline of Haemophilus influenzae type b disease in Australia. Commun Dis Intell 1997, 21:173-176.
23. Ramsay M.E., McVernon J., Andrews N.J., Heath P.T., Slack M.P. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003, 188:481-485.
24. Schmitt H.J., von Kries R., Hassenpflug B., Hermann M., Siedler A., Niessing W., et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001, 20(August (8)):767-774.
25. Dagan R., Fraser D., Roitman M., Slater P., Anis E., Ashkenazi S., et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Vaccine 1999, 17(2):134-141.
26. Diez-Domingo J., Pereiro I., Morant A., Gimeno C., San-Martin M., Gonzalez A. Impact of non-routine vaccination on the incidence of invasive Haemophilus influenzae type b (Hib) disease: experience in the autonomous region of Valencia, Spain. J Infect 2001, 42(4):257-260.
27. van Alphen L., Spanjaard L., van der Ende A., Schuurman I., Dankert J. Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr 1997, 131(6):869-873.
28. Hviid A., Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 2004, 22:378-382.
29. Cowgill K.D., Ndiritu M., Nyiro J., Slack M.P., Chiphatsi S., Ismail A., et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006, 296:671-678.
30. Madhi S.A., Petersen K., Khoosal M., Huebner R.E., Mbelle N., Mothupi R., et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002, 21:315-321.
31. Lagos R., Horwitz I., Toro J., San Martin O., Abrego P., Bustamante C., et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996, 15(3):216-222.
32. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005, 365:43-52.
33. Obonyo C.O., Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis 2006, 25(2):90-97.
34. Swingler G., Fransman D., Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections (Review). Cochrane Database Syst Rev 2007, (2):CD001729.
35. Huston P., Naylor C.D. Health services research: reporting on studies using secondary data sources. CMAJ 1996, 155(12):1697-1709.
36. Mulholland K., Hilton S., Adegbola R., Usen S., Oparaugo A., Omosigho C., et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997, 26(349):1191-1197.
37. Watt J.P., Wolfson L.J., O'Brien K.L., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009, 374:903-911.
38. Heath P.T., McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002, 86(6):396-399.
39. Murphy T.V., White K.E., Pastor P., Gabriel L., Medley F., Granoff D.M., et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 1993, 269(2):264-266.
40. Ribeiro G.S., Reis J.N., Cordeiro S.M., Lima J.B., Gouveia E.L., Petersen M., et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003, 187(1):109-116.
41. Shetty S., Cohen A.L., Edmond K., Ojo L., Loo J., O'Loughlin R., et al. A systematic review and critical evaluation of invasive Haemophilus influenzae type b disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. Pediatr Infect Dis J 2010, [Epub ahead of print].
42. World Health Organization Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec 2007, 12(82):93-104.
43. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303(10):549-552.
44. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
45. Whitney C.W., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.